Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.

TSXV:APC.H - Post Discussion

Advanced Proteome Therapeutics Corporation > Look at a 10 year chart, was over $ 4.00 and now $ .12 cents
View:
Post by up2005 on Sep 18, 2020 1:56am

Look at a 10 year chart, was over $ 4.00 and now $ .12 cents

Warrants aren't worth the paper if the company can't move this deal forward. This is one of my most could have, would have, should have stocks. The promise of greatness has been dangled for so long. Are we really getting close to something?
Comment by unionbroker on Sep 25, 2020 11:37am
Warrants are dead and news must be close by now . I think anything positive will move the share price higher
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities